-
Je něco špatně v tomto záznamu ?
Role of solute carrier transporters in pancreatic cancer: a review
R. Lemstrová, P. Souček, B. Melichar, B. Mohelnikova-Duchonova,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
ProQuest Central
od 2000-02-01 do 2020-12-31
Health & Medicine (ProQuest)
od 2000-02-01 do 2020-12-31
PubMed
25084206
DOI
10.2217/pgs.14.80
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom farmakoterapie genetika patologie MeSH
- chemorezistence genetika MeSH
- deoxycytidin aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- farmakogenetika * MeSH
- fluoruracil aplikace a dávkování škodlivé účinky MeSH
- lidé MeSH
- membránové transportní proteiny genetika MeSH
- nádory slinivky břišní farmakoterapie genetika patologie MeSH
- polymorfismus genetický MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membrane transporters and the potential applications for PDAC therapy with nucleoside analogues are summarized.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014114
- 003
- CZ-PrNML
- 005
- 20150505105706.0
- 007
- ta
- 008
- 150420s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/pgs.14.80 $2 doi
- 035 __
- $a (PubMed)25084206
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lemstrová, Radmila $u Department of Oncology, Palacky University Medical School & Teaching Hospital, Olomouc, Czech Republic.
- 245 10
- $a Role of solute carrier transporters in pancreatic cancer: a review / $c R. Lemstrová, P. Souček, B. Melichar, B. Mohelnikova-Duchonova,
- 520 9_
- $a Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). Decreased drug transport into tumor cells that may be caused by low expression of membrane proteins, such as solute carrier transporters, represents one of the principal mechanisms of chemotherapy resistance. Individual diversity of multidrug resistance is the major challenge limiting the success of anticancer treatment. Novel biomarkers and pharmacogenomic approaches could further optimize treatment algorithms leading to better survival and lower treatment toxicity in PDAC patients. In this review, the most promising predictive biomarkers from the solute carrier transporter family of membrane transporters and the potential applications for PDAC therapy with nucleoside analogues are summarized.
- 650 _2
- $a adenokarcinom $x farmakoterapie $x genetika $x patologie $7 D000230
- 650 _2
- $a deoxycytidin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D003841
- 650 _2
- $a chemorezistence $x genetika $7 D019008
- 650 _2
- $a fluoruracil $x aplikace a dávkování $x škodlivé účinky $7 D005472
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a membránové transportní proteiny $x genetika $7 D026901
- 650 _2
- $a nádory slinivky břišní $x farmakoterapie $x genetika $x patologie $7 D010190
- 650 12
- $a farmakogenetika $7 D010597
- 650 _2
- $a polymorfismus genetický $7 D011110
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Souček, Pavel
- 700 1_
- $a Melichar, Bohuslav
- 700 1_
- $a Mohelnikova-Duchonova, Beatrice
- 773 0_
- $w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 15, č. 8 (2014), s. 1133-45
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25084206 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150505110015 $b ABA008
- 999 __
- $a ok $b bmc $g 1071695 $s 896992
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 15 $c 8 $d 1133-45 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
- LZP __
- $a Pubmed-20150420
